192 related articles for article (PubMed ID: 31103901)
1. Salinomycin and its derivatives - A new class of multiple-targeted "magic bullets".
Antoszczak M; Huczyński A
Eur J Med Chem; 2019 Aug; 176():208-227. PubMed ID: 31103901
[TBL] [Abstract][Full Text] [Related]
2. A medicinal chemistry perspective on salinomycin as a potent anticancer and anti-CSCs agent.
Antoszczak M
Eur J Med Chem; 2019 Feb; 164():366-377. PubMed ID: 30611056
[TBL] [Abstract][Full Text] [Related]
3. A comprehensive review of salinomycin derivatives as potent anticancer and anti-CSCs agents.
Antoszczak M
Eur J Med Chem; 2019 Mar; 166():48-64. PubMed ID: 30684870
[TBL] [Abstract][Full Text] [Related]
4. Overcoming Resistance to Platinum-Based Drugs in Ovarian Cancer by Salinomycin and Its Derivatives-An In Vitro Study.
Michalak M; Lach MS; Antoszczak M; Huczyński A; Suchorska WM
Molecules; 2020 Jan; 25(3):. PubMed ID: 31991882
[TBL] [Abstract][Full Text] [Related]
5. Polymeric Micellar Formulation Enhances Antimicrobial and Anticancer Properties of Salinomycin.
Sousa C; Gouveia LF; Kreutzer B; Silva-Lima B; Maphasa RE; Dube A; Videira M
Pharm Res; 2019 Apr; 36(6):83. PubMed ID: 30989413
[TBL] [Abstract][Full Text] [Related]
6. Ester derivatives of salinomycin efficiently eliminate breast cancer cells via ER-stress-induced apoptosis.
Kuran D; Flis S; Antoszczak M; Piskorek M; Huczyński A
Eur J Pharmacol; 2021 Feb; 893():173824. PubMed ID: 33347821
[TBL] [Abstract][Full Text] [Related]
7. Salinomycin, as an autophagy modulator-- a new avenue to anticancer: a review.
Jiang J; Li H; Qaed E; Zhang J; Song Y; Wu R; Bu X; Wang Q; Tang Z
J Exp Clin Cancer Res; 2018 Feb; 37(1):26. PubMed ID: 29433536
[TBL] [Abstract][Full Text] [Related]
8. Salinomycin exerts anticancer effects on human breast carcinoma MCF-7 cancer stem cells via modulation of Hedgehog signaling.
Lu Y; Ma W; Mao J; Yu X; Hou Z; Fan S; Song B; Wang H; Li J; Kang L; Liu P; Liu Q; Li L
Chem Biol Interact; 2015 Feb; 228():100-7. PubMed ID: 25499043
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and Anticancer Activity of Tertiary Amides of Salinomycin and Their C20-oxo Analogues.
Czerwonka D; Urbaniak A; Sobczak S; Piña-Oviedo S; Chambers TC; Antoszczak M; Huczyński A
ChemMedChem; 2020 Jan; 15(2):236-246. PubMed ID: 31702860
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the anticancer activity of singly and doubly modified analogues of C20-epi-salinomycin.
Czerwonka D; Mielczarek-Puta M; Antoszczak M; Cioch A; Struga M; Huczyński A
Eur J Pharmacol; 2021 Oct; 908():174347. PubMed ID: 34265289
[TBL] [Abstract][Full Text] [Related]
11. Single and double modified salinomycin analogs target stem-like cells in 2D and 3D breast cancer models.
Urbaniak A; Reed MR; Fil D; Moorjani A; Heflin S; Antoszczak M; Sulik M; Huczyński A; Kupsik M; Eoff RL; MacNicol MC; Chambers TC; MacNicol AM
Biomed Pharmacother; 2021 Sep; 141():111815. PubMed ID: 34130123
[TBL] [Abstract][Full Text] [Related]
12. Combination of salinomycin and silver nanoparticles enhances apoptosis and autophagy in human ovarian cancer cells: an effective anticancer therapy.
Zhang XF; Gurunathan S
Int J Nanomedicine; 2016; 11():3655-75. PubMed ID: 27536105
[TBL] [Abstract][Full Text] [Related]
13. Salinomycin induces selective cytotoxicity to MCF-7 mammosphere cells through targeting the Hedgehog signaling pathway.
Fu YZ; Yan YY; He M; Xiao QH; Yao WF; Zhao L; Wu HZ; Yu ZJ; Zhou MY; Lv MT; Zhang SS; Chen JJ; Wei MJ
Oncol Rep; 2016 Feb; 35(2):912-22. PubMed ID: 26718029
[TBL] [Abstract][Full Text] [Related]
14. Antibacterial activity of singly and doubly modified salinomycin derivatives.
Sulik M; Stępień K; Stefańska J; Huczyński A; Antoszczak M
Bioorg Med Chem Lett; 2020 May; 30(9):127062. PubMed ID: 32147358
[TBL] [Abstract][Full Text] [Related]
15. Salinomycin derivatives exhibit activity against primary acute lymphoblastic leukemia (ALL) cells in vitro.
Urbaniak A; Delgado M; Antoszczak M; Huczyński A; Chambers TC
Biomed Pharmacother; 2018 Mar; 99():384-390. PubMed ID: 29367107
[TBL] [Abstract][Full Text] [Related]
16. Poly(lactic-co-glycolic acid) nanoparticles conjugated with CD133 aptamers for targeted salinomycin delivery to CD133+ osteosarcoma cancer stem cells.
Ni M; Xiong M; Zhang X; Cai G; Chen H; Zeng Q; Yu Z
Int J Nanomedicine; 2015; 10():2537-54. PubMed ID: 25848270
[TBL] [Abstract][Full Text] [Related]
17. Differences in Antiproliferative Activity Between Salinomycin-AZT Conjugates Obtained via 'Click' and Esterification Reactions.
Antoszczak M; Maj E; Kleczewska N; Wietrzyk J; Celewicz L; Huczynski A
Med Chem; 2017; 13(2):127-136. PubMed ID: 27557629
[TBL] [Abstract][Full Text] [Related]
18. Semisynthesis of SY-1 for investigation of breast cancer stem cell selectivity of C-ring-modified salinomycin analogues.
Huang X; Borgström B; Månsson L; Persson L; Oredsson S; Hegardt C; Strand D
ACS Chem Biol; 2014 Jul; 9(7):1587-94. PubMed ID: 24841425
[TBL] [Abstract][Full Text] [Related]
19. Co-Eradication of Breast Cancer Cells and Cancer Stem Cells by Cross-Linked Multilamellar Liposomes Enhances Tumor Treatment.
Kim YJ; Liu Y; Li S; Rohrs J; Zhang R; Zhang X; Wang P
Mol Pharm; 2015 Aug; 12(8):2811-22. PubMed ID: 26098197
[TBL] [Abstract][Full Text] [Related]
20. Salinomycin as a potent anticancer stem cell agent: State of the art and future directions.
Qi D; Liu Y; Li J; Huang JH; Hu X; Wu E
Med Res Rev; 2022 May; 42(3):1037-1063. PubMed ID: 34786735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
